Mark ShermanAssociated PressLatest in HomeSponsoredWhy Biocompatibility Plans Should Focus on Storytelling, Not Data DumpingApril 9, 2026Integer Going Private in $5.7B Acquisition DealAugust 3, 2026Octapharma Picks U.S. Site for $1.5B Manufacturing FacilityAugust 3, 2026Quasar Medical Acquires Nitinol Design and Development CenterJuly 31, 2026
